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Abstract Adipocytes not only store energy, but also secrete
biologically active molecules called adipocytokines, which play
a pivotal role in adipocyte-related pathological processes such as
diabetes and cardiovascular disease. Recent studies have shown
that preadipocyte/adipocyte expresses chemokines (e.g. mono-
cyte chemoattractant protein-1, macrophage in£ammatory pro-
tein-1 alpha) which alter adipocyte function, indicating the in-
volvement of chemokines in adipocyte-related pathologies. The
current study investigated the potential of macrophage in£am-
matory protein-related protein-2 (MRP-2), a novel CC chemo-
kine, to modulate preadipocyte tra⁄cking and adipocyte di¡er-
entiation. MRP-2 and its receptors were highly expressed in
preadipocytes and di¡erentiated adipocytes as well as in the
mouse fat pad. Chemotaxis assays revealed that MRP-2 was
a speci¢c chemotactic regulator in preadipocyte migration. The
levels of MRP-2 expression in adipose tissue were enhanced in
obese mice compared to lean mice. MRP-2 secretion by pre-
adipocytes was suppressed during di¡erentiation. MRP-2 sup-
pressed the expression of adipocyte di¡erentiation markers such
as adipocyte fatty acid-binding protein and glycerol-3 phosphate
dehydrogenase. Taken together, our data suggest that MRP-2
plays a role in the regulation of preadipocyte migration and
adipocyte di¡erentiation during adipose tissue development.
MRP-2 may be another adipocytokine, which can be involved
in the adipocyte-related pathological process.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Obesity is characterized by abnormal adipose tissue devel-
opment that has been clearly shown to increase health risks
such as diabetes and cardiovascular diseases. In obesity, body
fat mass increases through both the enlargement of existing
fat cells (hypertrophy) and the increase in adipocyte number
(hyperplasia). Preadipocyte migration into fat cell clusters is
an indispensable process in the initial stage of adipose tissue
development [1], indicating that uncontrolled migration of
preadipocytes may result in adipocyte hyperplasia and fat
mass increase in obesity. However, the molecules regulating
this process have not been identi¢ed. Adipocytes not only
store energy, but also secrete biologically active molecules
such as tumor necrosis factor-K (TNFK), interferon-Q
(IFNQ), interleukin-1 and -6, transforming growth factor-L,
leptin, and plasminogen activator inhibitor type 1 [2,3]. Those
molecules, which are called adipocytokines [4], modulate adi-
pose tissue metabolism and accelerate the adipocyte-related
pathological process. For example, TNFK inhibited insulin
action in adipocytes and thus caused obesity-related insulin
resistance [5]. Plasminogen activator inhibitor type 1 directly
regulated preadipocyte migration and angiogenesis, and thus
was implicated in adipose tissue expansion in obesity [6]. It is
now apparent that those adipocytokines act as contributing
factors to adipocyte-related in£ammatory diseases such as
diabetes and atherosclerosis [7,8].
Chemokines, a superfamily of structurally related small
(most being 8^14 kDa) chemotactic cytokines, are known as
in£ammatory mediators due to their ability to cause leukocyte
tra⁄cking to sites of in£ammation [9]. Besides the chemotac-
tic properties, chemokines also have broader biological func-
tions such as growth-regulatory and angiogenic properties
during the development of the immune system [10,11]. Inter-
estingly, recent studies have shown that human adipocytes
constitutively express CC chemokines such as monocyte che-
moattractant protein-1 (MCP-1), macrophage in£ammatory
protein-1K (MIP-1K) [12]. Those chemokines alter lipid accu-
mulation and leptin secretion by adipocytes [12], indicating
the involvement of chemokines in regulation of adipocyte
function. However, whether chemokines exhibit chemotactic
properties for the recruitment of non-immune cells such as
preadipocytes have not been reported.
Macrophage in£ammatory protein-related protein-2 (MRP-
2), a new member of the CC chemokine family, is a potent
chemoattractant for monocytes, lymphocytes, neutrophils,
and eosinophils [13]. Our previous studies have shown that
the levels of MRP-2 are enhanced in mice fed high fat diets
as well as in human atherosclerosis patients [14,15], indicating
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MRP-2 could be associated with the obesity-related patholog-
ical process. The current study investigated the potential of
MRP-2 to induce preadipocyte migration and to modulate
adipocyte function. Here, we present for the ¢rst time, the
evidence that MRP-2 is a potent chemoattractant for preadi-
pocyte, and the expression levels of MRP-2 in adipose tissue is
elevated in obese mice. In addition, we show that MRP-2 is
associated with regulation of adipocyte di¡erentiation. The
CC chemokine MRP-2 may be a critical factor in the regula-
tion of preadipocyte recruitment and adipocyte di¡erentiation
during adipose tissue development.
2. Materials and methods
2.1. Cell culture
3T3-L1 murine preadipocytes (ATCC) were cultured in a basal
medium consisting of Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 200 WM ascorbic acid, 10% calf serum,
100 U/ml penicillin, and 100 Wg/ml streptomycin at 37‡C in a 5% CO2
atmosphere. Two days after reaching con£uence (day 0), the cells were
incubated in a di¡erentiation medium containing the inducing mixture
(0.25 WM dexamethasone, 10 Wg/ml insulin, and 0.5 mM 1-methyl-3-
isobutylxanthine as in the basal medium. After 40 h, the cell culture
medium was changed to a maturation medium containing 5 Wg/ml
insulin with the basal medium, and fresh maturation medium was
changed every 2 days for 7 days [16].
2.2. Preparation of adipose tissue sample
To examine the MRP-2, chemokine receptor (CCR)-1 and CCR-3
mRNA or protein expression in the fat pad, epididymal adipose tissue
samples were isolated from Balb/c female mice. Obese (db/db obese,
8 weeks, male, Japan CLEA, Tokyo) and lean mice (C57BL, 8 weeks,
male, Japan CLEA, Tokyo) were used to examine the expression of
MRP-2, aP2, and leptin mRNA. The care and treatment of experi-
mental animals conformed to the NIH guidelines for the ethical treat-
ment of laboratory animals.
2.3. Chemotaxis assay
Cell migration was assessed in a multiwell microchemotaxis cham-
ber (Neuroprobe, USA). Brie£y, 3T3-L1 preadipocytes were sus-
pended in the DMEM medium at a concentration of 5U105 cells/ml
and 50 Wl of the cell suspension was placed into the upper well of a 96-
well chamber separated by a gelatin-coated 8-Wm polycarbonate ¢lter
from a lower well containing MRP-2. A medium that does not con-
tain additional MRP-2 served as the untreated control. In order to
assess MRP-2 or the receptor-speci¢c chemotaxis, anti-MRP-2 (50 Wg/
ml, RpD Systems, MN, USA), anti-CCR1 (50 Wg/ml, RpD Systems,
MN, USA), or anti-CCR3 (50 Wg/ml, RpD Systems, MN, USA) anti-
body was added to the culture medium for 30 min to neutralize MRP-
2 or CCR1/CCR3. Normal rat IgG or mouse IgG was used as the
negative control. The medium from untreated cells was used to deter-
mine basal migration. After incubation for 16 h at 37‡C, non-mi-
grated cells were removed by scraping. The cells that migrated across
the ¢lter were ¢xed and stained with Di¡-Quik (International Re-
agents Corp., Japan). Stained cells were counted in three randomly
chosen high-power ¢elds (U400) under a light microscope. Results
were expressed as meansPS.E.M. from triplicate samples.
2.4. Oil red-O staining
Adipocyte di¡erentiation was monitored by staining intracellular
lipid with oil red-O. Brie£y, cells were washed gently with PBS, ¢xed
in 10% formalin solution for 1 h, and washed in water. Cells were
treated with 60% isopropanol for 1 min, and then stained for 2 h at
room temperature with 0.18% oil red-O in 60% isopropanol. After
washing in 60% aqueous isopropanol, the cells were visualized.
2.5. RT-PCR analysis
Total RNA was extracted from 1U107 cells or from a 10 mg tissue
using a Tri-Reagent (MRC). Total RNA (0.5 Wg) was reverse-tran-
scribed into cDNA according to the manufacturer’s instructions. For
semiquantitative analysis, the linearity of ampli¢cation of MRP-2,
MIP-1K, adipocyte fatty acid-binding protein (aP2), glycerol-3 phos-
phate dehydrogenase (GPDH), leptin, CCR-1, CCR-3 and L-actin
cDNAs was established in preliminary experiments. 20 cycles for
aP2, leptin, 30 cycles for GPDH, MRP-2 and 40 cycles each for
CCR-1, CCR-3, MIP-1a ampli¢cation were found to be the optimum
conditions for obtaining a satisfactory pro¢le. The following sets of
primers were used in PCR ampli¢cation: MRP-2 (GenBank acces-
sion number U15209): forward, 5P-TGCCTGTCCTATAACTCACG-
GATT-3P, reverse, 5P-AGCAAATGTTATTGTTTGTAGGTCCG-3P ;
MIP-1K (X53372): forward, 5P-ACCAAGTCTTCTCAGCGCCAT-
3P, reverse, 5P-AAAATAGTCAACGATGAATTGGCG-3P ; adipocyte
fatty acid-binding protein (aP2) (K02109): forward, 5P-AAGAC-
AGCTCCTCCTCGAAGGTT-3P, reverse, 5P-TGACCAAATCCCC-
ATTTACGC-3P ; GPDH (J02655): forward, 5P-AGACACCCAAC-
TTTCGCATCAC-3P, reverse, 5P-CAATGGACTTTCCAGTTCGA-
GC-3P ; leptin (M96827): forward, 5P-AGCACTTGGTTCGCTAT-
CGCT-3P, reverse, 5P-TTCCCCACGTAGAGCGTTAGG-3P ; CCR-1
(NM001295): forward, 5P-AGTGGGAGTTCACTCACCGTACC-3P,
reverse, 5P-AGTAATAGCAAATATCAGACGCACGG; CCR-3
(AF026535): forward, 5P-ACAATTGACAGATACCTGGCTATC-
GT-3P, reverse, 5P-AAAAAGGAGAACCAGGTTGTACGG-3P ;
L-actin (X03672): forward, 5P-ATGAAGATCCTGACCGAGCGT-
3P, reverse, 5P-AACGCAGCTCAGTAACAGTCCG-3P. Ampli¢ca-
tion products obtained by PCR were electrophoretically separated
on a 2% agarose gel. SYBR green-stained bands for the target gene
and L-actin were photographed. The intensity of the bands was den-
sitometrically measured with a NIH image analyzer. All gene signals
were normalized to mRNA levels of the housekeeping gene, L-actin,
and expressed as a relative ratio.
2.6. Western blot analysis
Adipose tissue samples were prepared and their protein content was
determined. Equal amounts of protein (100 Wg/lane) were loaded and
electrophoresed on a 17% SDS^polyacrylamide gel. After transferring
the separated proteins to nitrocellulose membrane, the membrane was
incubated overnight in a blocking bu¡er (2% non-fat dry milk, 10 mM
Tris (pH 7.5), 100 mM NaCl and 0.1% Tween 20) and was treated
with a goat polyclonal MRP-2 antibody (RpD System, MN, USA)
for 2 h. After washing, the membrane was incubated with a horse-
radish peroxidase (HRP)-conjugated anti-goat IgG antibody. The im-
munoreactive protein was detected with a chemiluminescent system
(ECL kit, Amersham, UK). After exposure to an X-ray ¢lm, band
density was calculated from optical density with an image analyzer.
2.7. Measurement of MRP-2
Immunoplates (Nunc, Denmark) were coated with puri¢ed MRP-2
(2 Wg/ml, RpD Systems) in PBS (100 Wl/well) overnight at 4‡C. After
blocking, 100 Wl of the test sample was added to each well. A bio-
tinylated polyclonal anti-MRP-2 antibody (100 Wg/ml) was added (100
Wl/well) after washing, and then the plates were incubated for 1 h at
room temperature. After washing, HRP-labeled streptavidin was
added at 100 Wl/well and the plates were incubated for 30 min at
room temperature. The plates were washed before adding the sub-
strate kit (Pharmingen, San Diego, CA, USA), and the reaction was
quenched by the addition of 50 Wl of 0.4 M NaOH. The absorbance at
450 nm was measured using a microplate reader (Molecular Devices).
2.8. Statistical analysis
All experiments were repeated at least twice. Results were expressed
as meansPS.E.M. Statistical analysis was performed using ANOVA
and Duncan’s multiple range test. Di¡erences were considered to be
signi¢cant at P6 0.05.
3. Results
3.1. Expression of MRP-2 and the receptors in fat cells and fat
tissue
The expression of MRP-2 and its receptors at the mRNA
level in 3T3-L1 preadipocytes, di¡erentiated adipocytes, and
fat pad was investigated. RT-PCR and Western blot analysis
revealed that MRP-2 mRNA/protein is expressed in both the
epididymal fat pad and the 3T3-L1 cells (Fig. 1A,B). Our data
revealed, for the ¢rst time, that fat cells constitutively ex-
pressed MRP-2. Interestingly, the expression of MRP-2 un-
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changed in di¡erentiated adipocyte (Fig. 1C), whereas the
expression of MIP-1K, a family of CC chemokine, was
down-regulated, as previously reported [10]. The expression
of CCR1 and CCR3 mRNA was also observed in the 3T3-
L1 preadipocytes, adipocytes, and fat pad (Fig. 1D). MRP-2
was detected in macrophage (RAW264.7), ¢broblast
(NIH3T3), and B lymphocyte hybridoma (145.2c.11), but
not in T lymphoma cell line (EL4). MRP-2 mRNA is widely
expressed in most organs (e.g. liver, lung, thymus, heart) ex-
cept brain [17]. Consistent with the previous report, MRP-2
was not detected in the brain.
3.2. Chemotaxis of 3T3-L1 preadipocytes by MRP-2
In order to determine whether MRP-2 can activate 3T3-L1
preadipocytes that express CCR1 and CCR3, speci¢c recep-
tors of the CC chemokine MRP-2, we examined whether
Fig. 1. Expression of MRP-2 and its receptor at mRNA or protein level in murine 3T3-L1 preadipocytes, di¡erentiated adipocytes, and mouse
fat tissue. Total RNA was extracted from 3T3-L1 preadipocytes, di¡erentiated adipocytes, and mouse epididymal adipose tissue. A: MRP-2
mRNA expression by RT-PCR analysis. B: MRP-2 protein expression by Western blot analysis. Recombinant MRP-2 served as the positive
control. C: MIP-1K mRNA expression by RT-PCR analysis D: CCR1 and CCR3 mRNA detected by RT-PCR. (E) MRP-2 mRNA expression
in various cell lines. Data presented is a representative of three independent experiments.
Fig. 2. Chemotaxis of 3T3-L1 preadipocytes by MRP-2. A: 3T3-L1 preadipocytes were exposed to MRP-2 (0.1^1000 ng/ml) or a vehicle for
16 h and cells migration was determined as described in Section 2. A medium that does not contain MRP-2 served as the untreated control.
Migration was expressed as percentage of the untreated control. B: Preincubation with a neutralizing anti-MRP-2 or anti-CCR-1/CCR-3 anti-
body resulted in signi¢cant inhibition of chemotaxis, whereas preincubation with non-immune isotypes of mouse IgG or rat IgG had no e¡ect.
Migration was expressed as percentage of the MRP-2 (10 ng/ml)-treated control. Values are meansPS.E.M. from three independent experi-
ments. *P6 0.05, **P6 0.01, signi¢cantly di¡erent from control.
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MRP-2 could induce preadipocyte migration. Using a chemo-
taxis assay we observed that MRP-2 is a strong chemoattrac-
tant for 3T3-L1 preadipocytes (Fig. 2A). MRP-2 (0.1^1000
nM) induced chemotactic migration in a bell-shaped response
pattern with an optimal response at 10 ng/ml. This MRP-2-
induced chemotactic migration was signi¢cantly (P6 0.01) in-
hibited by the anti-MRP-2 or anti-CCR-1/CCR-3 antibodies
(Fig. 2B), whereas the non-immune isotype of mouse IgG or
rat IgG had no e¡ect.
3.3. Expression of MRP-2 in adipose tissues of obese and lean
mice
To examine whether MRP-2 expression is upregulated in
obesity, we compared the levels of MRP-2 mRNA expression
in epididymal and perirenal adipose tissues from obese and
lean mice. The expression of MRP-2 was upregulated 2.5 fold
in obese epididymal and 2.2 fold in perirenal adipose tissue
compared to lean mice (Fig. 3A). The expression of leptin and
aP2 mRNA in the fat tissue, which is known to be enhanced
in obesity, was signi¢cantly upregulated in obese mice com-
pared to those the expression in lean mice (Fig. 3B), as pre-
viously reported [18^20].
3.4. MRP-2 release by 3T3-L1 preadipocytes
Lipid accumulation in di¡erentiated adipocytes was deter-
mined by oil-red O staining (Fig. 4A). The release of MRP-2
Fig. 3. Expression of MRP-2, aP2, or leptin mRNA in epididymal and perirenal adipose tissues of obese and lean mice. Epididymal and perire-
nal adipose tissues are isolated from obese (N=5) and lean mice (N=5), and total RNA was extracted from the adipose tissues. The expres-
sions of MRP-2, aP2, leptine mRNA were measured by RT-PCR analysis and the intensity of the bands was densitometrically measured and
normalized to mRNA levels of L-actin. Open boxes show the data for lean mice and closed boxes the data for obese mice. Values are meansP
S.E.M. *P6 0.001, **P6 0.01, signi¢cantly di¡erent from control.
Fig. 4. MRP-2 release by 3T3-L1 preadipocytes and di¡erentiated adipocytes. At 48 h after reaching con£uence, 3T3-L1 preadipocytes were in-
cubated in the di¡erentiation medium containing 0.25 WM dexamethasone, 10 Wg/ml insulin, and 0.5 mM 1-methyl-3-isobutylxanthine. After
40 h, the cell culture medium was changed to the maturation medium containing 5 Wg/ml insulin, and the maturation medium was replaced
with a fresh one every 2 days for 7 days. At day 7, lipid accumulation in adipocytes was determined by oil red-O staining. The amount of
MRP-2 protein released by preadipocytes or adipocytes was measured by ELISA as described in Section 2. AL Oil red-O staining. B: MRP-2
release. Values are meansPS.E.M. from three independent experiments. *P6 0.01, signi¢cantly di¡erent from the undi¡erentiated control.
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by 3T3-L1 adipocytes before and after di¡erentiation was
detected in the culture medium. 3T3-L1 preadipocytes di¡er-
entiated in the inducing mixture, then underwent maturation
for 7 days. Undi¡erentiated 3T3-L1 cells produced MRP-2
(113P 11 pg/ml), the production of which was signi¢cantly
(P6 0.01) reduced during di¡erentiation (7P 0.6 pg/ml), as
shown in Fig. 4B. The amount of released MRP-2 gradually
increased and reached maximal levels (214P 26 pg/ml) at day
2 of maturation, and returned toward baseline of the undi¡er-
entiated cells at day 6 of maturation.
3.5. E¡ect of MRP-2 on the expression of aP2 and GPDH
mRNA
Because MRP-2 release by preadipocytes decreased during
di¡erentiation, we examined whether MRP-2 could a¡ect cell
di¡erentiation where exogenous mediators promoted adipo-
genesis. MRP-2 treatment during adipocyte di¡erentiation re-
sulted in suppression of adipocyte-speci¢c di¡erentiation
markers such as message expression of aP2 and GPDH at
day 6 after induction of di¡erentiation (Fig. 5). Troglitazone,
a synthetic thiazolidinedione derivative, which is known to
promote adipocyte di¡erentiation [16] resulted in upregulation
of the adipocyte-speci¢c di¡erentiation markers.
4. Discussion
In the present study, we revealed for the ¢rst time the role
of the CC chemokine MRP-2 in the recruitment of preadipo-
cytes and adipogenesis.
The CC chemokine MRP-2 is known to be a chemotactic
cytokine, recruiting leukocytes into the sites of in£ammation
and activating the cells [13]. However, it is not known whether
that chemokine can act as a modulator to induce chemotaxis
for non-immune cells and/or to alter their functions. Our data
showed that MRP-2 mRNA and protein are highly expressed
in murine 3T3-L1 preadipocytes, di¡erentiated adipocytes,
and mouse adipose tissue. The expression of MRP-2 in an
adipocyte cell line as well as in adipose tissue of normal
mice indicates that MRP-2 might modulate adipocyte func-
tion, and not be limited to the recruitment of immune cells. It
has been shown previously that preadipocytes constitutively
express CC chemokine (e.g. MCP-1, MIP-1K) and their recep-
tors [12], and that expression of chemokine mRNA was de-
creased in di¡erentiated adipocytes compared with preadipo-
cytes. It is important to note, however, that mRNA steady-
state levels of MRP-2 did not decrease in di¡erentiated adi-
pocytes compared to preadipocytes, whereas MIP-1K expres-
sion decreased in adipocytes as previously reported [12]. The
results indicate that there may be a role for regulation of
adipocyte function. Mouse adipose tissue and 3T3-L1 cells
also expressed the receptors CCR1 and CCR3. That receptor
expression in preadipocytes and adipocytes suggests that
MRP-2 may function as an autocrine or a paracrine regulator
of both preadipocytes and adipocytes.
Since the recruitment of leukocytes are mediated by the
chemokines and their speci¢c receptor signaling, we thought
that preadipocytes may respond to MRP-2-induced chemo-
taxis in a manner similar to other immunocompetent cells
such as monocytes. Our data clearly revealed that 3T3-L1
preadipocytes exhibited the ability to migrate when treated
with the CC chemokine MRP-2. The treatment with the
anti-MRP-2 or anti-CCR-1/CCR-3 antibody blocked MRP-
2-induced migration. Those results indicated that preadipo-
cytes had the same chemotactic properties as monocytes medi-
ated by speci¢c receptors. Considering the fact that preadipo-
cyte migration into fat cell clusters is a prerequisite for
adipose tissue development, the e¡ect of MRP-2 on preadipo-
cyte migration has signi¢cant physiological relevance in adi-
pose tissue development. It has been reported that chemokines
exhibit growth regulatory and angiogenic properties [11,12,
21], which can also a¡ect tissue development. Therefore, our
result could be interpreted that MRP-2 produced locally by
preexisting adipocytes may play an important role in recruit-
ing preadipocytes into adipocyte clusters.
The chemotactic properties of MRP-2 for preadipocytes led
us to speculate that MRP-2 may be associated with abnormal
adipose tissue development in obesity. To ¢nd the potential
involvement of MRP-2 in obesity, we determined the di¡er-
ence of the levels of MRP-2 expression in lean and obese
mice. Our data revealed that the levels of MRP-2 expression
of epididymal adipose tissue were markedly enhanced in obese
mice compared to those of lean mice. Consistent with other
reports [18^20], upregulation of aP2 and leptin expression was
observed in the adipose tissues from obese mice. Considering
the chemotactic properties of MRP-2, the upregulation of
MRP-2 in fat tissues may cause abnormal adipose tissue ex-
pansion in the obese mice.
Interestingly, it has been shown that preadipocytes exhib-
ited functional features of macrophages, such as phagocytosis
and anti-microbial activity, suggesting that preadipocytes play
a role in the in£ammatory process and in an immune response
[22]. MRP-2-induced preadipocyte tra⁄cking in our observa-
Fig. 5. E¡ect of MRP-2 on the levels of aP2 and GPDH mRNA expression in adipocyte. 3T3-L1 preadipocytes were incubated in the di¡eren-
tiation medium containing 0.25 WM dexamethasone, 10 Wg/ml insulin, and 0.5 mM 1-methyl-3-isobutylxanthine. Total cellular RNA was iso-
lated at 6 days after the induction of di¡erentiation. The expressions of aP2 (A), GPDH (B) mRNA were measured by RT-PCR analysis. Data
presented is a representative of three independent experiments.
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tions strongly supports the idea that preadipocytes could mi-
grate to in£ammatory sites and directly a¡ect in£ammatory
processes mimicking macrophages. It has been reported that
obese subjects have a higher incidence of atherosclerosis. Our
previous studies demonstrated that MRP-2 expression was
upregulated in atherosclerotic lesions, especially in foam
cell-rich areas [14,15]. Therefore, alternatively, MRP-2 may
contribute to the recruitment of preadipocytes into the ath-
erosclerotic lesion sites.
The secretion of MRP-2 from both preadipocytes and dif-
ferentiated adipocytes was detected. Interestingly, the release
of MRP-2 by preadipocytes was markedly decreased when the
inducing mixture was added. It has been previously shown
that MRP-2 suppressed colony formation by bone marrow
stem and progenitor cells, suggesting that MRP-2 is associated
with cell di¡erentiation [13]. Recent studies have indicated
potential regulation of adipogenesis by a chemokine signaling
pathway (e.g. MIP-1K and MCP-1) [12]. These results support
the idea that MRP-2 may function as a regulatory molecule in
adipocyte di¡erentiation. When the expression of di¡erentia-
tion markers was measured in adipocytes, we found that
MRP-2 suppressed the expression of aP2 and GPDH
mRNA in mature adipocytes, indicating that MRP-2 inhibited
adipocyte di¡erentiation. Our results together with those of
others suggest that MRP-2 may modulate adipogenesis. Fur-
ther studies are needed to demonstrate the mechanism of
MRP-2 action in adipogenesis.
In conclusion, MRP-2 and its receptors are highly expressed
in adipose tissue and 3T3-L1 cells. MRP-2 functions as a
chemotactic modulator in preadipocyte migration. The levels
of MRP-2 expression in adipose tissue were enhanced in obese
mice. MRP-2 secretion by preadipocytes is suppressed during
di¡erentiation. Moreover, MRP-2 inhibited the expression of
aP2 and GPDH mRNA in 3T3-L1 adipocytes. Taken togeth-
er, our data suggest that MRP-2 plays an important role in
the recruitment of preadipocytes and adipocyte di¡erentiation
during adipose tissue development. MRP-2 may be another
adipocytokine which is important in the adipocyte-related
pathological process.
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